Acute severe visual acuity decrease after photodynamic therapy with verteporfin: Case reports from randomized clinical trials - TAP and VIP report no. 3

American Journal of Ophthalmology

Volumn 137, Issue 4, 2004, Pages 683-696

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE;

CHOROID; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; FLUORESCENCE; FOLLOW UP; HUMAN; MORPHOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA HEMORRHAGE; RETINA PIGMENT EPITHELIOPATHY; REVIEW; VISUAL ACUITY; VISUAL IMPAIRMENT;

EID: 1842556553     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2003.11.059     Document Type: Article

References (8)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin one-year results of two randomized clinical trials - TAP report 1. Arch Ophthalmol. 117:1999;1329-1345.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin two-year results of two randomized clinical trials - TAP Report 2. Arch Ophthalmol. 119:2001;198-207.
3. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy report 2. Am J Ophthalmol. 131:2001;541-560.
4. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP), Verteporfin in Photodynamic Therapy (VIP) Study Groups. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of two-year safety results in three randomized clinical trials - TAP and VIP report No. 4. Retina 2003. Forthcoming.
5. Verteporfin Roundtable 2000 and 2001 Participants, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Principal Investigators, Verteporfin In Photodynamic Therapy (VIP) Study Group Principal Investigators. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina. 22:2002;6-18.
6. Miller J.W., Schmidt-Erfurth U., Sickenberg M., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol. 117:1999;1161-1173.
7. Schmidt-Erfurth U., Miller J.W., Sickenberg M., et al. Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration results of retreatments in a phase 1 and 2 study. Arch Ophthalmol. 117:1999;1177-1187.
8. Reinke M.H., Canakis C., Husain D., et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the Cynomolgus monkey. Ophthalmology. 106:1999;1915-1923.